The study identifies MAPK pathway involvement in GP-DPR toxicity but doesn't explain the molecular mechanism linking GP-DPRs to MAPK activation. Understanding this pathway is critical for developing targeted therapeutics for C9ORF72-ALS/FTD. Gap type: unexplained_observation Source paper: Divergent Molecular Pathways for Toxicity of Selected Mutant C9ORF72-derived Dipeptide Repeats. (None, None, PMID:37808871)
Landscape Summary: How do GP-DPRs activate MAPK signaling to disrupt axonal transport and synaptic function? is a 0.82 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How do GP-DPRs activate MAPK signaling to disrupt axonal transport and synaptic function? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: